Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9959710 | 0.85 | KDM4E (0.38) | RORCKDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL9987421 | 0.85 | F2RL3 (0.47) | KDM4EHPGDALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL30084130 | 0.84 | PTGER1 (0.38) | KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL173515 | 0.81 | PTGER1 (0.38) | KDM4EHPGDALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2732363 | 0.81 | DCLK1 (0.40) | HPGDALDH1A1HSD17B10L3MBTL1PTGER1 | |
| SCHEMBL30084116 | 0.81 | PTGER1 (0.38) | KDM4EHPGDALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2733380 | 0.81 | MKNK1 (0.33) | KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL12193840 | 0.81 | NAMPT (0.33) | KDM4EHPGDALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14859602 | 0.80 | ACSS2 (0.43) | — | |
| SCHEMBL173456 | 0.79 | L3MBTL1 (0.57) | HPGDSMN1; SMN2L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2584903-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2584903-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MAPK1, MAPK6, MAPK3 | CSNK2A2 1352/4885CSNK2B 1335/4885RORC 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.